Drugs / HS-20089
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06769425 | May 2025 → May 2026 overdue | female breast carcinoma, gastric cancer, ovarian cancer, prostate cancer +1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06336707 | Apr 2024 → Apr 2026 overdue | cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05263479 | Jan 2022 → Dec 2024 overdue | neoplasm | Shanghai Hansoh Biomedical Co., Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06014190 | Dec 2023 → Dec 2025 overdue | endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06855069 | Mar 2025 → Mar 2027 expected | ovarian carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20089 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05263479 ↗ |
| Action | Inhibit | “it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo.” NCT05263479 ↗ |
| Modality | Monoclonal antibody | “humanized IgG1 anti-B7-H4 monoclonal antibody” NCT06336707 ↗ |
| Route | Intravenous | “IV administration of HS-20089 Q3W” NCT05263479 ↗ |